Related Experiment Video

Updated: Apr 5, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Monoclonal Antibodies in Multiple Myeloma Come of Age

Noopur Raje1, Dan L Longo

  • 1From the Massachusetts General Hospital Cancer Center and Harvard Medical School - both in Boston (N.R.).

The New England Journal of Medicine
|August 27, 2015
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Related Experiment Videos

Last Updated: Apr 5, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.9K

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

18.6K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

Articles linked to this work by shared authors, journal, and citation graph.

Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis.

Leukemia·2026

High-Risk Smoldering Multiple Myeloma: A Review of Controversies in Early Treatment Versus Observation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM-3.

Cancer·2026

Persistence of PET scan positivity after chemoimmunotherapy for DLBCL.

Blood advances·2026

Age-driven shifts in T and NK cell responses amplify inflammation and coagulopathy during viral infection in mice and humans.

Frontiers in immunology·2026

Quantitative bias analyses to address measurement error in time-to-event endpoints.

American journal of epidemiology·2026

Targeting METTL3/m6A/SOCS3 axis reprograms tumor-associated macrophage polarization to potentiate the efficacy of anti-PD-1 therapy in multiple myeloma.

Cellular and molecular life sciences : CMLS·2026

Distinct clinical and immunologic patterns of interferon-γ release assays: implications for indeterminate results and sequential testing strategies.

Microbiology spectrum·2026

Recalcitrant Infectious Keratitis in DOCK8 Immunodeficiency Syndrome.

Journal of pediatric ophthalmology and strabismus·2026

Early but not serial ustekinumab concentration measurements are associated with clinical outcomes in Crohn's disease and ulcerative colitis: the Stockholm Ustekinumab study (STOCUSTE).

European journal of gastroenterology & hepatology·2026

Cost comparison of intravenous immunoglobulin and subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyneuropathy.

Journal of medical economics·2026

Head-to-head comparison of [18F]AlF-NOTA-JR11 PET/MR and [68Ga]Ga-DOTA-TATE PET/CT in patients with neuroendocrine tumors.

European journal of nuclear medicine and molecular imaging·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us